In: The Journal of Infectious Diseases, 2005, vol. 191, no. 9, p. 1419-1426
|
In: Clinical Infectious Diseases, 1995, vol. 20, no. 3, p. 531-541
|
In: Clinical Infectious Diseases, 2007, vol. 44, no. 1, p. 94-102
|
In: The Journal of Infectious Diseases, 1999, vol. 180, no. 3, p. 659-665
|
In: Clinical Infectious Diseases, 1997, vol. 24, no. 5, p. 965-970
|
In: The Journal of Infectious Diseases, 2000, vol. 182, no. 1, p. 334-337
|
In: Clinical Infectious Diseases, 1997, vol. 24, no. 4, p. 620-624
|
In: Clinical Infectious Diseases, 2011, vol. 52, no. 4, p. 532-539
|
In: Clinical Infectious Diseases, 1995, vol. 21, no. 3, p. 690-691
|
In: Neurology, 2013, vol. 80, no. 6, p. 553–560
Objective: To assess the efficacy and safety of rivastigmine for the treatment of HIV-associated neurocognitive disorders (HAND) in a cohort of long-lasting aviremic HIV+ patients.Methods: Seventeen aviremic HIV+ patients with HAND were enrolled in a randomized, double-blind, placebo-controlled, crossover study to receive either oral rivastigmine (up to 12 mg/day for 20 weeks) followed by placebo...
|